Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI may predict transfusion needs to shield ICU patients from organ failure

NCT ID NCT07762131

Knowledge-focused Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This study is testing whether an artificial intelligence model can predict which critically ill patients in the intensive care unit (ICU) are at risk of developing multiple organ dysfunction syndrome (MODS), a serious complication where two or more organs fail. Researchers will collect data from about 2,600 adult ICU patients, including lab results, vital signs, and transfusion details, to build and validate the AI model. The goal is to help doctors make more precise transfusion decisions, potentially reducing organ failure and improving outcomes. This is an observational study, meaning no treatments are assigned—the AI model is being developed and tested using existing patient data.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Red blood cell transfusion exposure (observational, no intervention)
What this could lead to
If successful, this could lead to a personalized transfusion decision-support tool that helps doctors reduce organ failure and improve survival in ICU patients.
What could go wrong
This is an observational study, so it can only find associations, not prove cause and effect. The AI model may not work perfectly in all hospitals or patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,598 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study includes adult critically ill patients admitted to intensive care units. Clinical data including demographic characteristics, underlying diseases, severity indicators, laboratory parameters, transfusion-related information, and clinical outcomes will be collected from electronic medical records. The study population will be used to develop an artificial intelligence-based prediction model for precision transfusion management and risk assessment of multiple organ dysfunction syndrome in critically ill patients.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients (aged ≥18 years) admitted to the intensive care unit. * Patients with available clinical data, including demographic characteristics, laboratory parameters, transfusion-related information, and clinical outcomes. * Patients meeting the requirements for model development and analysis. Exclusion Criteria: * Patients younger than 18 years. * Patients with missing key clinical information required for analysis. * Patients with repeated ICU admissions during the study period (only the first ICU admission will be included). * Patients whose data cannot be used for research purposes according to ethical requirements.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Blood transfusion are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Critical Illness multiple organ dysfunction syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Blood transfusion Critical illness Multiple organ dysfunction syndrome

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.